| Income Statement | 2025-09-30 | 2025-06-30 | 2025-03-31 | |
|---|---|---|---|---|
| Total other income (expense), net | 2,969 | 3,208 | 3,518 | |
| Net loss | -20,171 | -21,563 | -12,928 | |
| Unrealized holding gains on available-for-sale investments | 73 | 0 | 29 | |
| Foreign currency translation adjustment | -10 | -52 | -10 | |
| Total other comprehensive income | 63 | -52 | 19 | |
| Total comprehensive loss | -20,108 | -21,615 | -12,909 | |
| Earnings per share, basic, total | -0.56 | -0.6 | -0.36 | |
| Net loss per share attributable to common stockholders, diluted | -0.56 | -0.6 | -0.36 | |
| Weighted average number of shares outstanding, basic, total | 35,850,037 | 35,850,037 | 35,850,037 | |
| Weighted average number of shares outstanding, diluted, total | 35,850,037 | 35,850,037 | 35,850,037 | |
BioAge Labs, Inc. (BIOA)
BioAge Labs, Inc. (BIOA)